Close
23 August 2022
Travel disruptions: transport along neurones in MND
4 August 2022
The generation of synthetic placebo data for…
28 July 2022
EnCouRaging the future of MND research
7 July 2022
ENCALS 2022 highlights: award-winning research
24 June 2022
Delving deeper into neurofilament light chain
17 June 2022
Behind the research… ENCALS 2022 Conference Highlights
What does the FDA approval of AMX0035 mean for the UK MND community?

What does the FDA approval of AMX0035 mean for the UK MND community?

Reading Time: 5 minutes On 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States. Two countries have approved AMX0035, with Canada conditionally approving the drug, known there as Albrioza, back in June 2022. The Canadian approval is dependent on the results of the ongoing…

Revisited: should routine genetic testing be considered for all cases of MND?

Revisited: should routine genetic testing be considered for all cases of MND?

Reading Time: 6 minutes The recent publication of the results from the Phase 3 Tofersen trial, an experimental gene therapy for the treatment of MND in people with a change in the gene that instructs the SOD1 protein, has provided increasing confidence that Tofersen is having a beneficial effect in people living with SOD1 MND. This and the development…

EnCouRaging the future of MND research

EnCouRaging the future of MND research

Reading Time: 5 minutes On the 19-20 July 2022, the MND Association welcomed early career researchers, and people living with and affected by MND to the University of Northampton for the inaugural MND EnCouRage UK event. The unique two-day event was aimed at recognising, retaining and encouraging the important work of early career researchers who will be the future…